Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs.
$3.82+6.41%
报价 2026-11-06
市值
$231M
EV
$341.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -60.0%
$3.59$9.56
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| VNDAVanda Pharmaceuticals Inc. | $231M | +6.4% | +20.3% | 93.2% | – | – | – | |
| ACHVAchieve Life Sciences, Inc. | $691.5M | +5.4% | – | 0% | – | – | – | |
| CAPRCapricor Therapeutics, Inc. | $521.2M | +4.7% | +18885.7% | 0% | – | 0.5x | – | |
| ALLOAllogene Therapeutics, Inc. | $359.3M | -4.6% | – | 0% | – | – | – | |
| AVIRAtea Pharmaceuticals, Inc. | $345.7M | +2.1% | -19.7% | 0% | – | – | – | |
| SGMTSagimet Biosciences Inc. | $320.9M | +8.0% | -90.0% | 0% | – | – | – | |
| ARCTArcturus Therapeutics Holdings Inc. | $294.2M | +10.6% | -81.3% | 24% | – | – | – | |
| IMRXImmuneering Corporation | $238.3M | +9.2% | +1836.4% | 0% | – | – | – | |
| TRDAEntrada Therapeutics, Inc. | $190.4M | +7.5% | -36.1% | -754.7% | – | – | – | |
| 同行中位数 | – | – | -27.9% | 0% | – | 0.5x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。